TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject-reported history of dry eye disease in both eyes for at least 6 months;~* History of use of artificial tear eye drops for dry eye symptoms;~* Total score of ≥40 on SANDE;~* TFBUT;~* Corneal fluorescein staining;~* Lissamine green conjunctival staining;~* Schirmer's test score.~Exclusion Criteria:~* Have participated in a previous tavilermide (MIM-D3) study;~* Have clinically significant slit lamp findings at Visit 1;~* Have a history of lacrimal duct obstruction within 12 months of Visit 1;~* Have an uncontrolled systemic disease;~* Be a woman who is pregnant, nursing or planning a pregnancy;~* Be a woman of childbearing potential who is not using an acceptable means of birth control;~* Have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study;~* Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 45 days prior to Visit 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 1% Tavilermide ophthalmic solution (Type: EXPERIMENTAL): None
- 5% Tavilermide ophthalmic solution (Type: EXPERIMENTAL): None
- Vehicle ophthalmic solution (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Study of DW-0919 & DW-0920 in Healthy Male Volunteers Under Fasting Condition

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult males aged 20 to 55 years at screening.~* No significant congenital/chronic disease.~* No symptoms in physical examination.~* Appropriate subjects as determined by past medical history, laboratory tests, serology and urinalysis.~* Be able to understand the objective, method of the study, the characteristics of investigational drug, and comply with the requirement of the study. Subject must provide written informed consent prior to study participation.~Exclusion Criteria:~* History of Hyperreactivity with drug ingredients(acetaminophen, tramadol) or opioids.~* History or presence of liver, kidney, or nervous system disease, respiratory disorders, endocrinological disorders, hemato-oncologic, cardiovascular or psychiatric or cognitive disorders.~* History of gastrointestinal disorders (bleeding, ulceration, hemorrhoids, piles) or disorders of absorption, distribution, metabolism, excretion.

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- DW-0919 (Type: ACTIVE_COMPARATOR): None
- DW-0920 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Background Noise for Adult Patients' Sleep Quality in Intensive Care Unit.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age must be greater than or equal to 20 years old.~* Admitted to the ICU and have been intubated for at least 24 hours.~* Aware of people, time, and place, and without hearing impairment.~* Be able to communicate in writing.~* The Glasgow Coma Scale score must be equal to or greater than 11, with a vocal response of 1 in the patient post-endotracheal tube placement.~Exclusion Criteria:~* History of insomnia, Alzheimer's disease, or depression.~* Routine use of sedative-hypnotic drugs (opioids, benzodiazepines, non-benzodiazepines, antihistamines, and melatonin) before admission.~* Post-operation in the operating room before ICU admission.~* ICDSC score of at least 4 or CAM-ICU positive.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- background noise group (Type: EXPERIMENTAL): Background noise at bedtime.
- conventional treatment group (Type: NO_INTERVENTION): Treatment as usual.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The SOLVE-IT National Randomized Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Self-identifies as Latino, black, or Caucasian~* Men who have sex with men~* Not HIV infected~* Engaged in unprotected anal sex at least twice in the 90 days before study entry with a nonprimary male partner~* Has broadband access during course of study~* Lives in United States~* Biological male~Exclusion Criteria:~* History of nonprescription drug injection use~* Has participated in SOLVE-IT at any phase

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 24 Years
- Healthy Volunteers: f

Study Arms:
- SOLVE-IT (Type: EXPERIMENTAL): Participants will receive the intervention SOLVE-IT. The SOLVE-IT intervention is a videogame designed to optimize self-regulation, reduce shame, and reduce risky choices for young men who have sex with men (YMSM).
- Waitlist Control (Type: ACTIVE_COMPARATOR): Participants will receive the intervention, SOLVE-IT, a video game designed to optimize self-regulation reduce shame, and reduce risky sexual choices for YMSM, after a 6-month waitlist period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of symptomatic macular PCV in the study eye~* A qualifying vision score at study entry~* A qualifying lesion size in the study eye at study entry~Exclusion Criteria:~* Active inflammation or infection in the study eye~* Uncontrolled intraocular pressure in the stuy eye~* Ocular condition in the study eye which may impact vision and confound study outcomes~* Prior treatment of the study eye with anti-VEGF therapy, verteporfin PDT, other laser and surgical interventions, intraocular corticosteroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab + vPDT (Type: EXPERIMENTAL): Treatment initiation with Ranibizumab and verteporfin PDT (vPDT), with re-treatment need (either Ranibizumab alone or combined with vPDT) determined at monthly visits based on defined retreatment criteria
- Ranibizumab monotherapy (Type: ACTIVE_COMPARATOR): Treatment initiation with Ranibizumab and Sham PDT, with re-treatment need (either Ranibizumab alone or combined with Sham PDT) determined at monthly visits based on defined retreatment criteria

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Early Occupational Therapy Intervention in the Hospital Discharge After Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of stroke with single or multiple vascular lesions that have occurred in the same time period, demonstrated by neuroimaging tests (CT or MRI).~* 18 years of age or older.~* Patient must live a maximum of 30 minutes away from the hospital center.~* Must present \> 2 or \<26 points on the National Institute of Health scale (NIHSS) and 45-100 points on the Barthel Index (BI) on the second day of the stroke (with BI 100, the patient can be included if the Montreal Cognitive Assessment is \<26).~* Patient must present some motor deficit that makes it difficult to carry out his ADL.~* Inclusion in the study occurs prior to hospital discharge.~Exclusion Criteria:~* NIHSS\> 26 and BI \<45.~* Life expectancy \<1 year.~* Previous stroke, dementia or other types of illnesses associated with dementia and other neurological, psychiatric or medical illnesses (for example, severe epilepsy, head trauma, schizophrenia, COPD, severe or unstable heart disease, sleep apnea) that could alter cognitive function.~* Does not understand Spanish or English.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control group (Type: NO_INTERVENTION): Usual care.
- OT intervention. (Type: EXPERIMENTAL): Patients and their caregivers assigned to the experimental group are included in an early occupational therapy intervention program.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adaptive Treatment for Alcohol and Cocaine Dependence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. meet DSM-IV criteria for lifetime cocaine or alcohol dependence and have used cocaine or alcohol in the prior 6 months;~2. be \> 18 years of age;~3. be judged clinically appropriate for IOP (e.g., no current psychotic disorder or evidence of severe dementia, and no acute medical problem requiring inpatient treatment;~4. have no regular IV heroin use during the past year;~5. have access to a telephone;~6. be willing to be randomized and participate in research; and~7. no current participation in methadone or other forms of DA treatment, other than IOP. Finally, because of study follow-up requirements, subjects will~8. be required to be metropolitan area residents, and~9. be able to provide the name, verified telephone number, and address of at least two contacts who can provide locator information on the patient during follow-up. We will include patients with dependence on other substances, provided that they are cocaine dependent and meet other inclusion criteria.~Exclusion Criteria:~1. have a current psychotic disorder (as assessed with the psychotic screen from the MINI) or evidence of dementia severe enough to prevent participation in outpatient treatment;~2. have acute medical problem requiring immediate inpatient treatment; or~3. are currently participating in methadone or other forms of DA treatment, other than IOP.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1-MI-IOP Engaged (Type: ACTIVE_COMPARATOR): Randomized to treatment as usual, and they attend regularly but dropped out of treatment after randomization.
- 2-MI-IOP Non-Engaged (Type: EXPERIMENTAL): Randomized to treatment as usual, and do not attend.
- 3-MI-PC Engaged (Type: ACTIVE_COMPARATOR): Randomized to treatment choice, but remain attending treatment as usual then dropped out of treatment after randomization.
- 4-MI-PC Non-engaged (Type: EXPERIMENTAL): Randomized to treatment choice, and do not attend treatment as usual, so the choice option is used.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy in Treating Patients With Resected Colon Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the colon that has been curatively resected within 42 days prior to entry, as follows: Stage II (T3-4 N0 M0, Modified Astler-Coller B2/3), i.e., tumor invasion of the wall of the colon or extension into the pericolonic tissue Stage III (any T N1-3 M0), i.e., tumor invasion of any depth No sarcoma, lymphoma, or carcinoid histology No laparoscopically assisted colectomy unless performed on protocol NCCTG-934653 (intergroup study INT-0146) Entire tumor located above the peritoneal reflection on surgical exploration or more than 15 cm from anal verge on endoscopy Involved adjacent structures (e.g., bladder, small intestine, ovary) removed en bloc with histologically negative margins More than 1 synchronous primary colon tumor allowed Most advanced tumor used for stage assignment No previous or synchronous rectal cancer Intestinal obstruction allowed Preliminary or complementary colostomy allowed Walled-off perforation allowed No free perforation, i.e., free air or fluid in abdomen No prior invasive colon or rectal malignancy regardless of disease-free interval~PATIENT CHARACTERISTICS: Age: Not specified Performance status: ECOG 0-2 Life expectancy: At least 10 years (excluding cancer diagnosis) Hematopoietic: WBC at least 4,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin normal AST or ALT normal Renal: Creatinine normal Cardiovascular: No active ischemic heart disease No NYHA class III/IV status No myocardial infarction within 6 months No symptomatic arrhythmia within 6 months Other: No nonmalignant systemic disease that precludes protocol treatment No psychiatric or addictive disorder that precludes informed consent No second malignancy within 10 years except: Effectively treated nonmelanomatous skin cancer Surgically cured carcinoma in situ of the cervix Lobular carcinoma in situ of the breast No pregnant women Effective contraception required of fertile patients~PRIOR CONCURRENT THERAPY: See Disease Characteristics No prior chemotherapy or radiotherapy

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): 5-FU + Leucovorin
- Group 2 (Type: EXPERIMENTAL): Uracil/Ftorarur + leucovorin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
General Inclusion Criteria:~* Patient has type 2 diabetes mellitus~* Patient is inadequately controlled and not on treatment with insulin or oral antihyperglycemic therapy~General Exclusion Criteria:~* Patient has a history of type 1 diabetes mellitus or history of ketoacidosis~* Patient was on antihyperglycemic agent therapy (oral or insulin) within the prior 12 weeks~* Patient was on \>4 weeks (cumulatively) of antihyperglycemic therapy (oral or insulin) over the prior 3 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Sitagliptin phosphate (+) metformin hydrochloride
- 2 (Type: ACTIVE_COMPARATOR): pioglitazone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Breast Displacement and CT Radiation Dose

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* scheduled for CT of the abdomen and pelvis at Harborview Medical Center~* able to provide written informed consent~Exclusion Criteria:~* Inability to provide written consent for self (minor, intubated, sedated, mentally incapacitated, in excessive physical distress)~* Chest or breast surgery within the previous 8 weeks~* Breast implants~* Open wounds to the chest wall~* Fractures of the ribs or spine within the previous 3 months~* Patients requiring oxygen therapy~* Mastectomy~* Breast radiation therapy~* Scarring to the breasts which would prevent displacement~* Claustrophobia is not an absolute exclusion criterion, but patient comfort will be a primary concern.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Standard CT (Type: NO_INTERVENTION): Women assigned to undergo CT using the standard dose reduction methods (including bismuth shielding and tube current modulation) but without the Chrysalis device.
- Chrysalis CT (Type: EXPERIMENTAL): Women assigned to undergo CT using the standard dose reduction methods (including bismuth shielding and tube current modulation) plus application of the Chrysalis device for breast displacement.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, 2 years or older~* Confirmed diagnosis of Gaucher disease by the enzymatic activity assay~* Stable Gaucher disease~* Treatment with imiglucerase (Cerezyme®) for at least 2 years and on a stable maintenance regimen (dose and regimen unchanged, except for situation of drug shortage) for at least the last six months~* Able to provide written informed consent~Exclusion Criteria:~* Currently taking another experimental drug for any condition~* History of allergy to carrots~* History of allergy to beta lactam antibiotics~* Previous infusion reaction suspected to be allergic in nature to Cerezyme® or Ceredase® or receiving premedication to prevent infusion reactions~* Presence of HIV and/or HBsAg and/or hepatitis C infection~* Presence of unresolved anemia due to iron, folic acid or vitamin B12 deficiency~* Presence of any significant comorbidity that could confound the interpretation of the clinical response to taliglucerase alfa~* Presence of any medical, emotional, behavioral or psychological condition that in the judgment of the Investigator would interfere with the patient's compliance with the requirements of the study

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Taliglucerase alfa (Type: EXPERIMENTAL): Open label taliglucerase alfa treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* good physical health~Exclusion Criteria:~* history of an abnormal Pap (Papanicolaou) test or abnormal cervical biopsy results~* history of HPV-related condition~* history of known prior vaccination with an HPV vaccine~* pregnant~* user of recreational or illicit drugs~* history of severe allergic reaction, including known allergy to any vaccine component~* immunocompromised~* history of certain medications or is currently taking or has taken certain medications (details will be discussed at the time of consent)~* has thrombocytopenia or other coagulation disorder~* concurrently enrolled in a clinical study of investigational agent

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Adult Women 27- to 45-years Old (Type: EXPERIMENTAL): Adult women 27- to 45-years old will receive V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.
- Young Adult Women 16- to 26-years Old (Type: ACTIVE_COMPARATOR): Young adult women 16- to 26-years old will receive V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine Versus Clonidine in TAP Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I-II physical status patients.~* Age between 3 and 8 years.~* Children undergoing laparoscopic orcheopexy.~Exclusion Criteria:~* Parent refusal~* History of developmental delay or mental retardation, which will make observational pain intensity assessment difficult~* Hypersensitivity to any local anesthetics~* Bleeding diathesis~* History of renal, hepatic, cardiac, upper or lower airway or neurological diseases~* Any sign of infection at the puncture site of the proposed block~* History of sleep apnea with which postoperative ventilation may be required

- Gender: MALE
- Minimum Age: 3 Years
- Maximum Age: 8 Years
- Healthy Volunteers: f

Study Arms:
- DEXMEDETOMIDINE (Type: ACTIVE_COMPARATOR): patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml each side + 0.5 ug/kg dexmedetomidine Hydrochloride dissolved in 2 ml normal saline (NaCl 0.9%).
- CLONIDINE (Type: ACTIVE_COMPARATOR): patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 0.5 ug/kg clonidine dissolved in 2 ml normal saline (NaCl 0.9%).
- LEVOBUPIVACAINE (Type: ACTIVE_COMPARATOR): patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (NaCl 0.9%).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete